Dr. David Peritt, Ph.D.

Chief Technology Officer

A cellular immunologist by training, Dr. Peritt has substantial industry experience in biologics and cell therapy R&D. Throughout his 30 year career working in academic, industrial, governmental, and military institutes, Dr. Peritt has developed life-saving therapies for hematological malignancies and autoimmune diseases. Before Sigilon, Dr. Peritt held various leadership positions including, Program Lead for Cell and Gene Therapy at Pfizer, Head of Biosimilars Biology at Hospira, and Scientific Lead for Strategic Investment in Cell Therapy for Hospira. He has led research efforts at several divisions of Johnson & Johnson including Centocor and Therakos and worked in governmental agencies such as the USDA, Walter Reed Army Medical Center, and the Sharrett Cancer Institute.

Dr. Peritt has numerous patents and publications to his name, as well as several therapies on the market that improve the lives of patients. He received his Ph.D. and post-doctoral training in immunology from the University of Pennsylvania and the Wistar Institute.

‹ Back